Powered by

Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results

Aug 06, 2019 - GlobeNewswire
Board and Executive Moves-Financial Results

-EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo--Clinical Response Observed Consistent with Reductions in Cellular Histological and Blood Immune Cell Biomarkers in Psoriasis Patients at Low Dose of EDP1815-- EDP1815 Phase 2 Initiation Planned for Early 2020--Positive EDP1066 Blood Immune Cell Biomarker Data in Psoriasis Patients at High Dose--First in Human Data Suggest that Oral Biologics that Act on Cells in the Small IntestineModulate Systemic Inflamm...